Eikon Therapeutics, Inc. (EIKN)
| Market Cap | 324.03M |
| Revenue (ttm) | n/a |
| Net Income | -337.13M |
| EPS | -9.28 |
| Shares Out | 54.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 292,791 |
| Open | 6.06 |
| Previous Close | 6.04 |
| Day's Range | 5.58 - 6.10 |
| 52-Week Range | 5.01 - 17.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.33 (+306.86%) |
| Earnings Date | Nov 12, 2026 |
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent W... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $24.33, which is an increase of 306.86% from the latest price.
News
Eikon Therapeutics reports Q3 EPS ($1.59), consensus ($1.60)
As of September 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $461.7M. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into 1Q...
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to add...
Eikon Therapeutics Earnings release: Q3 2026
Eikon Therapeutics released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Eikon Therapeutics Quarterly report: Q3 2026
Eikon Therapeutics has published its Q3 2026 quarterly earnings report on November 12, 2026.
Eikon Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
ESMO results highlighted EIK1001’s tolerability and encouraging squamous lung cancer activity, with event-driven Phase II/III studies underway. Selective PARP1 programs showed combination potential and low hematologic toxicity; cash was $531.2 million at June 30.
Eikon Therapeutics Transcript: JP Morgan Biotech Call Series
Clinical programs span EIK1001, selective PARP1 inhibitors and a Werner helicase inhibitor, with additional data expected over the next 6–12 months. Key milestones include a melanoma interim in H1 2027 and definitive EIK1001 trial data estimated for mid-2029.
Eikon Therapeutics participates in a conference call with JPMorgan
Conference call with management to be held on November 6 at 1 pm hosted by JPMorgan.Webcast Link
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics presents updated EIK1001 data at ESMO
Eikon Therapeutics (EIKN) announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. “These updated results presented at ESMO f...
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
MILLBRAE, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics to present abstracts on clinical candidates at ESMO 2026
Eikon Therapeutics (EIKN) announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology, ESMO, Congress in Madrid...
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab an...
Eikon Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Eikon Therapeutics (EIKN) with a Buy rating and $23 price target Eikon is a clinical-stage biopharmaceutical company built around a proprietary single-molecule tr...
Eikon Therapeutics submits EIK1006 IND application to FDA
Eikon Therapeutics (EIKN) announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 ...
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted robust clinical progress across multiple oncology programs, including promising efficacy and safety data for EIK-1001 and highly selective PARP1 inhibitors. Financially, the company maintains a strong cash position to support ongoing and expanding clinical trials.
Eikon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Four clinical-stage drug candidates are advancing, including two highly selective PARP1 inhibitors with reduced toxicity and a TLR7/8 agonist in late-stage trials. Proprietary imaging technology accelerates drug discovery and supports expansion into new therapeutic areas. Cash reserves of $531.2 million support ongoing studies.
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
Eikon Therapeutics (EIKN) announced the appointment of Ching-Pin Chang as executive VP and chief scientific officer. Chang joins Eikon from Bristol Myers (BMY), where he most recently served as VP,…
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Transcript: KOL event
PARP1-selective inhibitors are positioned to address the hematologic toxicity of first-gen PARP inhibitors, enabling higher dosing, longer treatment, and more combination options. Eikon's clinical programs show promising early safety and efficacy, with key data to be presented at ESMO. Werner helicase inhibitors offer a new approach for MSI tumors, emphasizing disease control and tolerability.
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
Eikon Therapeutics reports Q2 EPS ($1.63), consensus ($1.46)
“The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for prese...
Eikon Therapeutics price target lowered to $4 from $5 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Eikon Therapeutics (EIKN) to $4 from $5 and keeps an Underperform rating on the shares. The firm notes the company…